Literature DB >> 2889164

Involvement of catecholaminergic neurones and alpha-adrenoceptors in the wet-dog shake and forepaw licking behaviour produced by the intrathecal injection of an analogue of thyrotrophin-releasing hormone (CG 3509).

K C Fone1, G W Bennett, C A Marsden.   

Abstract

Intrathecal injection of the analogue of TRH, CG 3509, into conscious rats produced dose-related wet-dog shakes and forepaw licking, which showed a bell-shaped relationship of intensity to dose. Pretreatment with alpha-MPT intraperitoneally, markedly reduced levels of noradrenaline and dopamine in the spinal cord and brainstem and attenuated both CG 3509-induced responses, while intrathecal treatment with DSP4 selectively reduced noradrenaline in the spinal cord without affecting either behaviour. Since denervation supersensitivity may develop following treatment with DSP4, these results are not inconsistent with a proposal that bulbospinal noradrenergic neurones modulate the behaviour induced by CG 3509. Wet-dog shakes and forepaw licking induced by CG 3509 were reduced by pretreatment with phenoxybenzamine or prazosin, suggesting that a tonic noradrenergic pathway may facilitate both behavioural responses through alpha 1-adrenoceptors. Methoxamine, combined with CG 3509 partially attenuated the wet dog shake behaviour, but methoxamine produced marked hindlimb jerking which might physiologically antagonise wet-dog shakes. Concomitant administration of clonidine and CG 3509 potently reduced wet-dog shakes in a dose-related manner but did not significantly affect forepaw licking, while idazoxan did not significantly affect either response. The latter findings imply that alpha 2-adrenoceptors play different roles in modulating the two behavioural responses and the possible synaptic location of the receptors is discussed. Taken together these results suggest that CG 3509 may release noradrenaline from bulbospinal neurones regulating motor function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2889164     DOI: 10.1016/0028-3908(87)90261-9

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Proceedings of the British Pharmacological Society. 6th-8th January, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

2.  Mutual independence of 5-HT(2) and α1 noradrenergic receptors in mediating deficits in sensorimotor gating.

Authors:  Sarah K Baisley; Katherine L Fallace; Abha K Rajbhandari; Vaishali P Bakshi
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

3.  Proceedings of the British Pharmacological Society. Liverpool, 6th-8th April, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

4.  Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats.

Authors:  K C Fone; J V Johnson; G W Bennett; C A Marsden
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

5.  Effect of chronic intra-accumbens administration of the TRH analogue CG3509 on histamine-induced behaviour in the rat.

Authors:  L J Bristow; G W Bennett
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

6.  Involvement of central alpha- and beta-adrenoceptors in the pressor response to electrical stimulation of the rostral ventrolateral medulla in rats.

Authors:  C Ward-Routledge; P Marshall; C A Marsden
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

7.  Effect of isolation rearing on 5-HT agonist-induced responses in the rat.

Authors:  I K Wright; H Ismail; N Upton; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats.

Authors:  K C Fone; A J Robinson; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.